

Phathom[®]

PHARMACEUTICALS

Phathom Pharmaceuticals to Present at Evercore ISI 2019 HealthCONx Conference

November 26, 2019

BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Nov. 26, 2019-- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Azmi Nabulsi, M.D., Chief Operating Officer, will present at the Evercore 2019 HealthCONx Conference on Tuesday, December 3 at 1:35 p.m. EST at the Four Seasons Hotel, Boston.

To access the live webcast and subsequent archived recordings for this presentation, which will be available for 30 days, please visit the Phathom Pharmaceuticals website at www.phathompharma.com.

About Phathom

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the company's website at www.phathompharma.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191126005253/en/>

Source: Phathom Pharmaceuticals, Inc.

David Socks
info@phathompharma.com
1-650-325-5156

Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312-961-2502
mikebeyer@sambrown.com

Investors:
Patti Bank
Westwicke Partners
415-513-1284
patti.bank@westwicke.com